Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographical data (at baseline)

From: Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)

  Intention to treat Per protocol
Number, number 52 49
Gender, female/male 31/21 29/20
Age, years 59.1 ± 10.8 59.3 ± 11.0
Body mass index, kg/cm 27.8 ± 5.3 27.8 ± 5.4
Disease duration, years 8.7 ± 8.2 8.3 ± 7.7
HAQ-DI, baseline 0.55 ± 0.66 0.58 ± 0.67
Tender joint count 68, mean ± SD 1.95 ± 2.97 2.11 ± 2.95
Swollen joint count 68, mean ± SD 0.55 ± 1.29 0.60 ± 1.30
Erythrocyte sedimentation rate, mm/h 11.37 ± 6.00 11.38 ± 7.0
C-reactive protein, mg/l 3.49 ± 2.00 6.28 ± 3.0
Patient’s global assessment of disease activity (VAS 0–100) 16.97 ± 13.26 15.81 ± 17.90
Patient’s global assessment of pain (VAS 0–100) 19.62 ± 16.61 18.05 ± 17.58
Physician’s global assessment of disease activity (VAS 0–100) 10.98 ± 9.28 14.33 ± 7.45
DAS-28 1.73 ± 0.72 1.82 ± 0.80
Rheumatoid factor-positivea 62.0 % 63.8 %
ACPA-positivea 50.0 % 51.1 %
Erosive diseasea 58.3 % 55.5 %
Pre-exposed to IV abatacept 38.5 % 34.6 %
Pre-exposed to TNF antagonists 60.1 % 53.4 %
Pre-exposed to other biologic agents 28.8 % 26.9 %
Concomitant therapy   
 Leflunomide n = 20 n = 19
 Leflunomide + hydroxychloroquine n = 1 n = 1
 Methotrexateb n = 18 n = 16
 Hydroxychloroquine n = 5 n = 5
 Sulfasalazine n = 4 n = 4
 Sulfasalazine + hydroxychloroquine n = 3 n = 3
Prednisolone dose or equivalent, mg/d 2.66 ± 3.25 2.82 ± 3.28
  1. aMeasured on patients with data assessable
  2. bMethotrexate was always applied in subcutaneous formulation
  3. HAQ-DI Health assessment questionnaire disability Index, SD standard deviation, ACPA anti-citrullinated peptide antibodies, VAS visual analog scale, DAS-28 disease activity score in 28 joints